Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Annika Eurola"'
Publikováno v:
Cancer Medicine, Vol 11, Iss 7, Pp 1605-1616 (2022)
Abstract Background Pancreatic cancer is one of the most prothrombotic cancers. Among patients receiving preoperative chemotherapy followed by surgery, chemotherapy and surgery represent a compound risk for venous thromboembolism (VTE), rendering the
Externí odkaz:
https://doaj.org/article/3cf0ce3defd3416bb9b238d4c0ce6d71
Autor:
Annika Eurola, Ari Ristimäki, Harri Mustonen, Anna-Maria Nurmi, Jaana Hagström, Caj Haglund, Hanna Seppänen
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Abstract Podocalyxin overexpression associates with poor survival in pancreatic cancer (PDAC). We investigated whether podocalyxin expression correlates with treatment response or survival in neoadjuvant-treated PDAC. Through immunohistochemistry, we
Externí odkaz:
https://doaj.org/article/6018413b766b4e3fbc35e9082e2e82a3
Autor:
Annika Eurola, Ari Ristimäki, Harri Mustonen, Anna-Maria Nurmi, Jaana Hagström, Pauliina Kallio, Kari Alitalo, Caj Haglund, Hanna Seppänen
Publikováno v:
Tumor Biology. 44:69-84
BACKGROUND: Wnt/β-catenin signaling is a highly conserved signaling pathway that regulates the transcription factor PROX1. The role of β-catenin and PROX1 in pancreatic cancer is ambiguous, as some studies have associated their expression with tumo
Autor:
Tiina Vuorela, Pirkka Vikatmaa, Arto Kokkola, Harri Mustonen, Aino Salmiheimo, Annika Eurola, Pekka Aho, Caj Haglund, Ilkka Kantonen, Hanna Seppänen
Roughly 10% - 20% of pancreatic cancer patients are candidates for curative intent surgical treatment. In the 2000s, many studies showed similar survival rates comparing pancreatic surgery with or without vein resection and reconstruction. The aim wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5c71babc97fb27d6ee39618670072e5
http://hdl.handle.net/10138/353812
http://hdl.handle.net/10138/353812